Drug Profile
KAN 0440550
Alternative Names: KAN-0440550Latest Information Update: 15 Sep 2023
Price :
$50
*
At a glance
- Originator Kancera
- Class Antineoplastics; Small molecules
- Mechanism of Action Receptor tyrosine kinase-like orphan receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Lymphoma
Most Recent Events
- 15 Sep 2023 Discontinued - Preclinical for Breast cancer in Sweden (PO) (Kancera pipeline, September 2023)
- 15 Sep 2023 Discontinued - Preclinical for Lymphoma in Sweden (PO) (Kancera pipeline, September 2023)
- 28 Sep 2020 No recent reports of development identified for preclinical development in Breast-cancer in Sweden (PO)